A Study to Evaluate How Well Etavopivat Works in People With Sickle Cell Disease
연구 개요
This study is conducted to confirm whether etavopivat works well at reducing the number of Vaso-occlusive crisis VOCs (sickle cell pain crises) caused by obstructions in blood vessels in adults and adolescents living with sickle cell disease. The study will also evaluate how well etavopivat can reduce the damage to different organs, improve your exercise tolerance and reduce fatigue in people with sickle cell disease.The participants will either get etavopivat or placebo. Which treatment the participants will get is decided by chance. Etavopivat is a new medicine and is currently being tested in other studies in addition to this one. The study will last for about 2 years.
- 스폰서
- 리드: 노보노디스크
- 적응증
- Sickle Cell Disease
- 중재
- Etavopivat, Placebo
- 목표 등록
- 408명
- 시작일
- 2025-02-17
- 완료(예정)
- 2029-03-12
BioPulse가 제공하는 정보는 공개된 자료를 요약·정리한 것으로, 투자 조언이나 의료 조언이 아닙니다. 임상 데이터·규제 일정·공시 내용은 반드시 원문을 직접 확인하시기 바랍니다.